Ana Lisa Basquiera

Médica Hematóloga. Hospital Privado Universitario de Cordoba. IUCBC. @SAHematologia
#BMT #CART #quality #cellulartherapy

[Ana Lisa Basquiera @basquiera]

Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th ECIL-Guidelines- The Lancet Infectious Diseases https://t.co/RDJDcHk1NK

[Eric Topol @EricTopol]

Deep B cell depletion is rebooting the immune system, the basis for a potential curative approach to a long list of autoimmune diseases
https://t.co/yIJCikSNe5

[ICCBBA @ISBT128]

How does the ISBT 128 Standard support cross-border traceability and patient safety across Europe? 🌍Read our latest blog to learn more.
🔗 https://t.co/GSFKQTcbP1
#ICCBBA #ISBT128Standard #Traceability #PatientSafety

[Unidad Académica de Hematología. @CatedraHemato]

Síndromes Mielodisplásicos de Bajo Riesgo. Abordaje diagnóstico y terapéutico @SofiaGrille @matilde_boada

[Ana Lisa Basquiera @basquiera]

FDA approves early warning system for sepsis https://t.co/D5gJ8iGfm9 via @HubJHU

[Felipe Peña-Muñoz @HematoRules]

Today in Dubrovnik at 8th International Chronic Graft-versus-Host Disease Symposium sharing the results of our Belumosudil analysis 🇮🇹 🇪🇸 🇬🇧 #cGvHD #HSTC

[Blood Journals Portfolio @BloodPortfolio]

HLA matching did not affect late transplantation outcomes after PT-Cy–based GVHD prophylaxis. Older donor age and female-to-male donor-recipient sex mismatch were associated with increased late NRM. Read in Blood Neoplasia: https://t.co/3zdPo31UcS

[Blood Cancer Journal @BloodCancerJnl]

Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-T. | Blood Cancer Journal https://t.co/evyALLAP1q

[Emma M. Groarke @emmamgroarke]

Super excited to share our How-I-Treat our today in @BloodPortfolio where we show how we integrate somatic mutations and other alterations 🧬 into the diagnosis and clinical care of #BMFsm patients. @fergutierrezro1 @bhavishap29 @NIH https://t.co/CnSeDfvc7E

[Dr Rudra Narayan Swain M.D , D.M @rudra09s025]

What should be the optimal strategy after AZA–VEN–induced remission in younger AML patients not proceeding to allo-HSCT?

Our recent work explores this clinically relevant question.
Read more in @BloodCancerJnl : 👉https://t.co/D2qYE1Vjbm

Grateful to @ArihantDr, @DrGPrakash, and @DrPMPGI Sir, for their invaluable support and conceptual guidance.
@AML_Hub #leusm #Hematology @blood_academy @SOAsocialmedia @ims_sum

[Matilde Boada @matilde_boada]

Invitados que son todo lo que está bien 💪🏻💪🏻💪🏻 Dr. Scott Howard @basquiera

[Unidad Académica de Hematología. @CatedraHemato]

Discusión de casos clínicos con un gran panel 💪🏻 @avazquez4 @basquiera

[Unidad Académica de Hematología. @CatedraHemato]

Finalizamos nuestro curso de Enfermería en CART con invitada de lujo @mercedesmontoro @hospitalclinic y una concurrencia excepcional presencial y virtual 👏👏 @Carlitocha Gracias a todos por acompañarnos

[Ana Lisa Basquiera @basquiera]

@CatedraHemato @SofiaGrille @Mariana17174661 @erivaserra @matilde_boada @SabrinaRanero @vicmatosas @ini_gervaz @leti_007 @andresaddiego Excelente evento académico! Gran nivel científico y oportunidad de networking.

[Unidad Académica de Hematología. @CatedraHemato]

4tas Jornadas Integradas de Hematología “Hematología al día” con un gran equipo 💪🏻 @SofiaGrille @Mariana17174661 @erivaserra @matilde_boada @SabrinaRanero @vicmatosas @ini_gervaz @leti_007 @andresaddiego

[Unidad Académica de Hematología. @CatedraHemato]

Leucemias agudas mieloblasticas en la era de los tratamientos target y los planes libres de quimioterapia @basquiera @matilde_boada @ini_gervaz @avazquez4

[Unidad Académica de Hematología. @CatedraHemato]

Mesa de lujo en Mieloma
Múltiple @erivaserra @basquiera

[Mostafa Faisal @MostafaFaisal14]

Efficacy of Low-Dose Olanzapine for the Prevention of Conditioning Therapy-Induced Nausea and Vomiting in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
https://t.co/UnyiQRPljU

[Mostafa Faisal @MostafaFaisal14]

Are HLA-Haploidentical Relatives a Donor Choice for Patients with Severe Aplastic Anemia? A GATMO-TC Experience @ASTCT_Journal
https://t.co/xY8SEDGqdJ

[Gonzalo Bentolila @GonzaloBentoli1]

Thrilled to share this collaborative work from GATMO-TC exploring whether HLA-haploidentical related donors may represent a donor choice for patients with severe aplastic anemia. A true multicenter effort from Argentina.
https://t.co/d25O8YA9mE